Meta-Regression of Adjunctive Treatment Trials for Negative and Other Residual Symptoms in Schizophrenia: A Differential Relationship of Treatment and Placebo Response With Sample Size

被引：0
|
作者：
Kantrowitz, Joshua [1 ]
Mayer, Megan [1 ]
Choo, Tse Hwei [1 ]
Liu, Kevin [1 ]
Govani, Viraj [1 ]
Francis, Shyanne [1 ]
Javitt, Daniel [1 ]
机构：
[1] Columbia Univ, New York, NY USA
来源：
NEUROPSYCHOPHARMACOLOGY | 2023年 / 48卷
关键词：
CNS Clinical Trials; Clinical Development; Negative Symptoms;
D O I：
暂无
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
P491
引用
收藏
页码：349 / 349
页数：1
相关论文
共 45 条
  • [21] The dose-effect relationship of acupuncture in the treatment of functional gastrointestinal disorders: A meta-regression of randomized controlled trials
    Gong, Siyao
    Yu, Xin
    Yang, Jiao
    Huang, Dan
    Yu, Shuguang
    Yang, Sha
    EUROPEAN JOURNAL OF INTEGRATIVE MEDICINE, 2024, 71
  • [22] Memantine add-on to antipsychotic treatment for residual negative and cognitive symptoms of schizophrenia: a meta-analysis
    Taro Kishi
    Yuki Matsuda
    Nakao Iwata
    Psychopharmacology, 2017, 234 : 2113 - 2125
  • [23] Memantine add-on to antipsychotic treatment for residual negative and cognitive symptoms of schizophrenia: a meta-analysis
    Kishi, Taro
    Matsuda, Yuki
    Iwata, Nakao
    PSYCHOPHARMACOLOGY, 2017, 234 (14) : 2113 - 2125
  • [24] Sildenafil adjunctive therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled trial
    Shahin Akhondzadeh
    Raofeh Ghayyoumi
    Farzin Rezaei
    Bahman Salehi
    Amir-Hossein Modabbernia
    Azad Maroufi
    Gholam-Reza Esfandiari
    Mehrangiz Naderi
    Fariba Ghebleh
    Mina Tabrizi
    Shams-Ali Rezazadeh
    Psychopharmacology, 2011, 213 : 809 - 815
  • [25] Cilostazol adjunctive therapy in treatment of negative symptoms in chronic schizophrenia: Randomized, double-blind, placebo-controlled study
    Rezaei, Farzin
    Mesgarpour, Bita
    Jeddian, Alireza
    Zeionoddini, Atefeh
    Mohammadinejad, Payam
    Salardini, Elaheh
    Shahriari, Mona
    Zeinoddini, Arefeh
    Akhondzadeh, Shahin
    HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2017, 32 (04)
  • [26] Sildenafil adjunctive therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled trial
    Akhondzadeh, Shahin
    Ghayyoumi, Raofeh
    Rezaei, Farzin
    Salehi, Bahman
    Modabbernia, Amir-Hossein
    Maroufi, Azad
    Esfandiari, Gholam-Reza
    Naderi, Mehrangiz
    Ghebleh, Fariba
    Tabrizi, Mina
    Rezazadeh, Shams-Ali
    PSYCHOPHARMACOLOGY, 2011, 213 (04) : 809 - 815
  • [27] Deconstructing depression and negative symptoms of schizophrenia; differential and longitudinal immune correlates, and response to minocycline treatment
    Krynicki, Carl R.
    Dazzan, Paola
    Pariante, Carmine M.
    Barnes, Nicholas M.
    Vincent, Rachel C.
    Roberts, Alex
    Giordano, Annalisa
    Watson, Andrew
    Suckling, John
    Barnes, Thomas R. E.
    Husain, Nusrat
    Jones, Peter B.
    Joyce, Eileen
    Lawrie, Stephen M.
    Lewis, Shon
    Deakin, Bill
    Upthegrove, Rachel
    BRAIN BEHAVIOR AND IMMUNITY, 2021, 91 : 498 - 504
  • [28] Factors affecting the efficacy and safety of phosphodiesterase 5 inhibitor and placebo in treatment for lower urinary tract symptoms: meta-analysis and meta-regression
    Sun, Hwa Yeon
    Lee, Bora
    Kim, Jae Heon
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2018, 50 (01) : 35 - 47
  • [29] Factors affecting the efficacy and safety of phosphodiesterase 5 inhibitor and placebo in treatment for lower urinary tract symptoms: meta-analysis and meta-regression
    Hwa Yeon Sun
    Bora Lee
    Jae Heon Kim
    International Urology and Nephrology, 2018, 50 : 35 - 47
  • [30] Estradiol and raloxifene as adjunctive treatment for women with schizophrenia: A meta-analysis of randomized, double-blind, placebo-controlled trials
    Li, Zijia
    Wang, Yucheng
    Wang, Zhe
    Kong, Lingtao
    Liu, Linzi
    Li, Liu
    Tang, Yanqing
    ACTA PSYCHIATRICA SCANDINAVICA, 2023, 147 (04) : 360 - 372
12345